Biohaven targets muscle-sparing obesity market to compete with Lilly's GLP-1 drugs

Biohaven is positioning itself to address obesity by developing treatments that preserve lean muscle, a differentiator from existing GLP-1 therapies.

The company sees an opportunity to act as a "shovel" provider in the rapidly expanding GLP-1 market, aiming to capture a share of the market that seeks weight loss without muscle loss.

By targeting this niche, Biohaven hopes to compete directly with Eli Lilly, which dominates the GLP-1 space, though the article does not detail any specific product or timeline.